Bryan Bergin, an analyst from TD Cowen, reiterated the Buy rating on Genpact. The associated price target remains the same with $55.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bryan Bergin has given his Buy rating due to a combination of factors that highlight Genpact’s strong performance and promising outlook. The company has shown robust growth in its Advanced Tech Solutions (ATS), with a notable 20% increase driven by the adoption of GenAI and agentic solutions. This growth has led to better-than-expected third-quarter results and an optimistic forecast for the fourth quarter, with improvements in revenue per capita and gross margin expansion.
Bergin also notes that Genpact’s strategic investments in GenAI are fueling demand from both existing and new clients, enhancing its financial profile. The company’s shares appear undervalued, trading at approximately 10 times the projected 2026 earnings. Additionally, Genpact’s ability to secure large deals and maintain a healthy pipeline supports its medium-term growth targets. The company’s focus on transitioning to non-FTE pricing models and disciplined capacity management has contributed to margin expansion, further justifying the Buy rating with a price target of $55.
According to TipRanks, Bergin is an analyst with an average return of -1.1% and a 44.09% success rate. Bergin covers the Technology sector, focusing on stocks such as Accenture, Block, and Genpact.
In another report released on October 30, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $42.00 price target.